Spots Global Cancer Trial Database for wdha syndrome
Every month we try and update this database with for wdha syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00075439 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | NCT00416767 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 80 Years | Federation Francophone de Cancerologie Digestive | |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | NCT00227617 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... Neuroendocrine ... | bevacizumab 5-fluorouracil leucovorin oxaliplatin | 18 Years - | University of California, San Francisco | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00027638 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... | thalidomide | - | Memorial Sloan Kettering Cancer Center | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00027638 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... | thalidomide | - | Memorial Sloan Kettering Cancer Center | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00075439 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | NCT00466856 | Head and Neck C... Islet Cell Tumo... Metastatic Canc... Pheochromocytom... | octreotide acet... yttrium Y 90 re... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00131911 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Neuroendocrine ... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | sorafenib tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | NCT00416767 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 80 Years | Federation Francophone de Cancerologie Digestive | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | NCT00006368 | Brain and Centr... Breast Cancer Gastrointestina... Islet Cell Tumo... Lung Cancer Lymphoma Melanoma (Skin) Neoplastic Synd... | yttrium Y 90-ed... | 18 Years - | Novartis | |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer | NCT00096083 | Cancer | isolated perfus... melphalan | 16 Years - | Delcath Systems Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
